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Mitochondria are fascinating organelles, at least in part, because
two membranes with very different permeability properties and
functions surround them. These membranes contribute to the
intracellular compartmentation between mitochondria and the
cytosol in eukaryotic cells. Thus, lipids (e.g., phospholipids, cho-
lesterol, cardiolipin), membrane proteins [e.g., voltage-dependent
anion channel (VDAC), ion exchangers, mitochondrial carriers
such as adenine nucleotide translocase (ANT)], as well as soluble
intermembrane space proteins cooperate to allow the channeling
of metabolites (e.g., ATP, ADP), ions (e.g., calcium, potassium,
sodium) and water across mitochondrial membranes. An increas-
ing body of literature suggests that mitochondrial proteins behave
also as control point in oncology (1, 2). For example, they can be
involved (i) in the metabolic shift of cancer cells from oxidative
phosphorylation to glycolysis via its binding to cytosolic proteins
such as hexokinase II (i.e., Warburg effect), (ii) in the control
of calcium fluxes between the endoplasmic reticulum (ER) and
the mitochondrion via interaction with the inositol-3-phosphate
receptor (IP3R), (iii) in the control of inner mitochondrial mem-
brane potential (∆Ψm) via interaction with tubulin and finally,
(iv) in the regulation of mitochondrial membrane permeability via
interaction with Bax/Bcl-2 family members and/or the mitochon-
drial permeability transition pore complex (PTPC). Moreover,
some proteins, via a shift in their expression, appear to be crit-
ical for the cancer cell response to chemotherapy (e.g., cisplatin,
oxaliplatin, carboplatin). However, how these diverse functions
are modulated and coordinated in cancer cells to control the bal-
ance between life and death is still largely unknown and requires
extensive review and discussion to broaden our view of the role of
mitochondrial proteins in oncology, the role of upstream signal-
ing pathways controlling mitochondrial function and how these
proteins and/or signaling pathways might be selective target for
anti-cancer therapy.
Thus, this research topic presents seven manuscripts, which
reviewed the current knowledge of mitochondrial proteins and
polyprotein complexes as druggable target for anti-cancer ther-
apy and also explored new putative targets. Thus, Suh et al.
reviewed the literature on the anti-cancer potential of the modu-
lation of the permeability transition pore, a megachannel in the
inner membrane (3). Sutendra and Michelakis proposed to reverse
mitochondrial suppression, which is an hallmark of many cancer
cells, with metabolic-modulating drugs, like pyruvate dehydro-
genase kinase (PDK) inhibitors or M2 isoenzyme of pyruvate
kinase (PKM2) activators as a novel anti-cancer strategy (4). In
a similar perspective, Rasola and Chiara discussed the mecha-
nistic interactions among oncogenic kinase pathways, glycogen
synthase kinase (GSK-3) activity and subsequent modulation of
mitochondrial functions that shape the pro-survival phenotype of
cancer cells, such as control of redox homeostasis and inhibition
of the mitochondrial permeability transition pore (5). In addi-
tion, Shoshan-Barmatz et al. review current evidence pointing to
the function of VDAC1 in cell life and death, and highlight these
functions in relation to cancer (6). Alternatively, Fulda proposed
to shift the balance of mitochondrial apoptosis to by pass evasion
of apoptosis and treatment resistance in human cancers (7).
Ishii et al. reviewed the accumulating knowledge on pyrvinium
pamoate, an FDA-approved anthelmintic, as an anti-cancer drug
targeting mitochondrial respiration (8). Interestingly, this drug
acts synergistically with dexamethasone to block the proliferation
if human myeloma cells and might be used in combination.
In a more exploratory approach, Kang and Pervaiz explored
the crosstalk between Bcl-2 family and Ras family small GTPases
(9). They analyzed their work and the recent literature to show
how this molecular crosstalk can regulate the cell fate. Previously,
they showed a converging role of Rac1 and Bcl-2 to promote a
pro-oxidant state, frequently observed in cancer cells. Despite the
complexity of GTPases family, they argued that the modulation of
the physical interactions between guanine exchange factors (GEF)
and GTPases could open new avenues for future redox-based
therapeutic designs.
We hope that this research topic provides new insights into the
role of mitochondrial proteins as major control points in oncology
and help the reader to elaborate new strategies for cancer therapy.
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